

Supplementary figure




Figure S1. Viability of B16F10 cells at 48 h after treatment (AI-1: Nrf2 activator; brusatol: Nrf2 inhibitor; Mito: endothelial mitochondria), as evaluated using the CCK8 assay. The AI-1 (10 μ M; Nrf2 activator) or brusatol (40 nM; Nrf2 inhibitor) was used to evaluate cell viability at 48 h by CCK-8. The results demonstrated that Nrf2 activator increased cell viability, however, Nrf2 inhibitor suppressed cell growth. Nrf2 inhibitor, brusatol, significantly reversed endothelial mitochondria-induced cell growth, suggesting that Nrf2 was involved in endothelial mitochondria transfer-mediated melanoma growth. Statistical analysis was used to determine if treatments were not significant, or significant compared to control (CTL) at $P < 0.01$ (**) or $P < 0.005$ (***) or significant compared to Mito group at $P < 0.005$ (###). Analysis was performed on five independent experiments and the mean values (\pm SEM) shown.